Sihuan Pharmaceutical Holdings Group (HKSE:00460) Risk Assessment

View and export this data going back to 2010. Start your Free Trial

What is Sihuan Pharmaceutical Holdings Group Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Sihuan Pharmaceutical Holdings Group is: Moderate Risk: Sensitive, better choose undervalued stock.

Competitive Comparison of Sihuan Pharmaceutical Holdings Group's Risk Assessment

For the Drug Manufacturers - Specialty & Generic subindustry, Sihuan Pharmaceutical Holdings Group's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sihuan Pharmaceutical Holdings Group's Risk Assessment Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sihuan Pharmaceutical Holdings Group's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Sihuan Pharmaceutical Holdings Group's Risk Assessment falls into.

Sihuan Pharmaceutical Holdings Group (HKSE:00460) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Sihuan Pharmaceutical Holdings Group Risk Assessment Related Terms

Thank you for viewing the detailed overview of Sihuan Pharmaceutical Holdings Group's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Sihuan Pharmaceutical Holdings Group (HKSE:00460) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sihuan Pharmaceutical Holdings Group Ltd (HKSE:00460) » Definitions » Risk Assessment

Traded in Other Exchanges

SHPHF:USA

Address

Zhubang 2000 Business Centre, 22nd Floor, Building 4, West Balizhuang, Chaoyang District, Beijing, CHN, 100025

Website

https://www.sihuanpharm.com

Sihuan Pharmaceutical Holdings Group Ltd is an investment holding company. Along with its subsidiaries, the company is engaged in the research & development and the manufacture & sale of pharmaceutical products. Its portfolio comprises products for diseases related to the cardio-cerebral vascular (CCV) system, Digestive System, Anti-Infective, metabolism, Respiratory, Neurology, and Others. The group has three reportable segments: the medical aesthetic products segment including the filling, shaping, supporting, supplementing, optoelectronic device, body sculpturing, skincare, and others to provide non- or minimally invasive medical aesthetics comprehensive solutions; the innovative medicine and other medicine segments; and the generic medicine segment.

Executives

Che Fengsheng	2201 Interest of corporation controlled by you
Guo Weicheng	2201 Interest of corporation controlled by you
Meng Xianhui	2201 Interest of corporation controlled by you
Zhang Jionglong	2201 Interest of corporation controlled by you
Mingyao Capital Limited	2401 A concert party to an agreement to buy shares
Network Victory Limited	2401 A concert party to an agreement to buy shares
Proper Process International Limited	2401 A concert party to an agreement to buy shares
Successmax Global Holdings Limited	2101 Beneficial owner
Victory Faith International Limited	2401 A concert party to an agreement to buy shares
Ubs Tc (jersey) Ltd	2301 Trustee
Ubs Trustees (cayman) Ltd.	2301 Trustee
Smart Top Overseas Limited	2501 Other
Plenty Gold Enterprises Limited	2307 Founder of a discretionary trust who can infl

Sihuan Pharmaceutical Holdings Group (HKSE:00460) Headlines

No Headlines